CHARLES J HOMCY
CIK 1192591 · Chairman of Pharmaceuticals · last filed 2026-06-24
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$79.00M
Companies
12
Total Filings
97
Lifetime Open-Market Net
-$51.69M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BBIO | Director | 919,876 | $84.64 | $77.86M | -$19.45M | 29 | 2026-06-24 |
| MAZE | Director | 38,535 | $27.17 | $1.05M | $0 | 6 | 2026-06-10 |
| PLRX | Director | — | $1.07 | — | $0 | 1 | 2021-06-30 |
| Population Health Investment Co., Inc. (PHICW) Delisted | Director | — | $0.00 | — | $0 | 1 | 2021-01-26 |
| PORTOLA PHARMACEUTICALS INC (PTLA) Delisted | Director | 132,471 | — | — | -$24.66M | 22 | 2019-04-01 |
| Global Blood Therapeutics, Inc. (GBT) Delisted | Director | 84,928 | $68.49 | $5.82M | -$5.09M | 10 | 2018-06-22 |
| MyoKardia, Inc. (MYOK) Delisted | Director | 6,496 | — | — | $0 | 2 | 2016-12-01 |
| CEPHALON INC (CEPH) Delisted | Director | — | — | — | $0 | 3 | 2011-10-17 |
| GERN | Director | 62,751 | $1.43 | $89.7K | $0 | 7 | 2011-05-13 |
| CYTK | Director | — | $78.93 | — | $0 | 3 | 2008-05-27 |
| MILLENNIUM PHARMACEUTICALS INC (MLNM) Delisted | Director | 0 | — | — | -$2.49M | 10 | 2008-05-15 |
| KOSAN BIOSCIENCES INC (KOSN) Delisted | Director | — | — | — | $0 | 1 | 2007-05-30 |
Recent Filings · Page 5 of 10
97 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-01-04 | PORTOLA PHARMACEUTICALS INC (PTLA) Delisted | Exer (M) | +45,923 | $234.2K | EDGAR |
| 2018-12-19 | PORTOLA PHARMACEUTICALS INC (PTLA) Delisted | Mixed | +25,782 | -$826.0K | EDGAR |
| 2018-11-16 | PORTOLA PHARMACEUTICALS INC (PTLA) Delisted | Exer (M) | +93,698 | $384.2K | EDGAR |
| 2018-06-22 | Global Blood Therapeutics, Inc. (GBT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-06-08 | PORTOLA PHARMACEUTICALS INC (PTLA) Delisted | Grant (A) | +3,000 | $0 | EDGAR |
| 2017-10-27 | Global Blood Therapeutics, Inc. (GBT) Delisted | Sell (S) | −70,000 | -$2.38M | EDGAR |
| 2017-10-05 | Global Blood Therapeutics, Inc. (GBT) Delisted | Sell (S) | — | $0 | EDGAR |
| 2017-06-27 | PORTOLA PHARMACEUTICALS INC (PTLA) Delisted | Mixed | — | -$5.81M | EDGAR |
| 2017-06-22 | Global Blood Therapeutics, Inc. (GBT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-06-22 | Global Blood Therapeutics, Inc. (GBT) Delisted | Sell (S) | −100,000 | -$2.71M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.